We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
Read MoreHide Full Article
Fortress Biotech (FBIO - Free Report) along with its partner company Cyprium Therapeutics announced that the two completed pivotal studies evaluating CUTX-101, its candidate for the treatment of patients with Menkes disease, achieved both primary and secondary efficacy endpoints.
Shares of Fortress increased 1.7% on Oct 8, following the news. Yet, the company’sstock price has declined 5.7% in the year so far in comparison with the industry’s 12.2% decline.
Image Source: Zacks Investment Research
Both the pivotal studies evaluated the comparison of the treatment of Menkes disease between participants who were administered CUTX-101 and those who were not administered CUTX-101. The studies divided these two participant populations into two cohorts — Early Treatment (ET) i.e., patients whose treatment was initiated within four weeks of birth, and Late Treatment (LT), patients whose treatment was initiated four weeks after birth.
Data from both the studies demonstrated that treatment with CUTX-101 in both cohorts achieved a significantly greater median overall survival (OS) in comparison to participants who were not treated with CUTX-101.
The primary and secondary efficacy endpoints of both the studies were comparison of OS in patients treated with CUTX-101 against patients not treated with the drug in ET and LT cohorts, respectively. Participants administered with CUTX-101 observed a reduction in the risk of death by 79% and 75% over participants not treated with the drug in the ET & LT cohorts, respectively.
Cyprium anticipates initiating a rolling submission of the new drug application for CUTX-101 to treat Menkes disease with the FDA in fourth-quarter 2021 based on the above-mentioned positive data from the two studies.
Menkes disease is a rare disease in pediatric patients that is caused by gene mutations of copper transporter ATP7A.
Please note that CUTX-101 is an investigational subcutaneous injectable formulation of copper histidinate (CuHis) being developed by Cyprium in partnership with Sentynl Therapeutics, which is owned by the Zydus Group. While Cyprium holds the development responsibility of the drug, Sentynl will be responsible for the commercialization of the candidate, once approved by the FDA.
Fortress Biotech currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Horizon Therapeutics , Regeneron Pharmaceuticals (REGN - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon’s earnings per share estimates for 2021 have increased from $4.46 to $4.67 in the past 60 days. The same for 2022 has risen from $5.84 to $6.23 over the same period. The stock has rallied 55.5% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $53.22 to $61.41 in the past 60 days. The same for 2022 has risen from $44.11 to $46.73 over the same period. The stock has rallied 13.9% in the year so far.
Vertex’s earnings per share estimates for 2021 have increased from $12.28 to $12.37 in the past 60 days. The same for 2022 has risen from $13.02 to $13.13 over the same period.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
Fortress Biotech (FBIO - Free Report) along with its partner company Cyprium Therapeutics announced that the two completed pivotal studies evaluating CUTX-101, its candidate for the treatment of patients with Menkes disease, achieved both primary and secondary efficacy endpoints.
Shares of Fortress increased 1.7% on Oct 8, following the news. Yet, the company’sstock price has declined 5.7% in the year so far in comparison with the industry’s 12.2% decline.
Both the pivotal studies evaluated the comparison of the treatment of Menkes disease between participants who were administered CUTX-101 and those who were not administered CUTX-101. The studies divided these two participant populations into two cohorts — Early Treatment (ET) i.e., patients whose treatment was initiated within four weeks of birth, and Late Treatment (LT), patients whose treatment was initiated four weeks after birth.
Data from both the studies demonstrated that treatment with CUTX-101 in both cohorts achieved a significantly greater median overall survival (OS) in comparison to participants who were not treated with CUTX-101.
The primary and secondary efficacy endpoints of both the studies were comparison of OS in patients treated with CUTX-101 against patients not treated with the drug in ET and LT cohorts, respectively. Participants administered with CUTX-101 observed a reduction in the risk of death by 79% and 75% over participants not treated with the drug in the ET & LT cohorts, respectively.
Cyprium anticipates initiating a rolling submission of the new drug application for CUTX-101 to treat Menkes disease with the FDA in fourth-quarter 2021 based on the above-mentioned positive data from the two studies.
Menkes disease is a rare disease in pediatric patients that is caused by gene mutations of copper transporter ATP7A.
Please note that CUTX-101 is an investigational subcutaneous injectable formulation of copper histidinate (CuHis) being developed by Cyprium in partnership with Sentynl Therapeutics, which is owned by the Zydus Group. While Cyprium holds the development responsibility of the drug, Sentynl will be responsible for the commercialization of the candidate, once approved by the FDA.
Fortress Biotech, Inc. Price
Fortress Biotech, Inc. price | Fortress Biotech, Inc. Quote
Zacks Rank & Stocks to Consider
Fortress Biotech currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Horizon Therapeutics , Regeneron Pharmaceuticals (REGN - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon’s earnings per share estimates for 2021 have increased from $4.46 to $4.67 in the past 60 days. The same for 2022 has risen from $5.84 to $6.23 over the same period. The stock has rallied 55.5% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $53.22 to $61.41 in the past 60 days. The same for 2022 has risen from $44.11 to $46.73 over the same period. The stock has rallied 13.9% in the year so far.
Vertex’s earnings per share estimates for 2021 have increased from $12.28 to $12.37 in the past 60 days. The same for 2022 has risen from $13.02 to $13.13 over the same period.